Dark

Check out our Level2View

BVAXF
BIOVAXYS TECHNOLOGY CORP
stock OTC

EOD

Jul 31, 2026

0.1100USD-6.383%(-0.0075)31,496

Pre-market

0.00USD-100.000%(-0.12)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Dec 7, 2021

08:01AM EST Biovaxys Announces Major Research Collaboration With The Ohio State University PR Newswire

Nov 18, 2021

08:42AM EST Therapeutic Advances in Vaccines and Immunotherapy to Submit a Review Article on Haptenized Protein Vaccine Platform PR Newswire

Nov 17, 2021

08:01AM EST BioVaxys Co-Founder and Chief Medical Officer David Berd, MD, to Present at PR Newswire

Nov 9, 2021

08:02AM EST Ranging In Vivo Clinical Pathology, Immunology, and Histopathology Evaluation, Supporting Planned Clinical Development of CoviDTH PR Newswire

Oct 28, 2021

08:02AM EDT BioVaxys Further Expands Intellectual Property Portfolio in Global Markets PR Newswire

Oct 20, 2021

08:05AM EDT BioVaxys Files US Patent Application For Pan-Sarbecovirus Vaccine RTTNews

Oct 8, 2021

03:00AM EDT BioVaxys Announces BVX-0320 Poster Presentation at ISIRV-WHO Virtual Conference PR Newswire

Sep 28, 2021

08:01AM EDT BioVaxys Begins Toxicity Study Ahead of CoviDTH IND Submission PR Newswire

Sep 23, 2021

03:00AM EDT BioVaxys Prepares for Groundbreaking Study on reduced ACE2 binding capabilities PR Newswire

Sep 20, 2021

12:02PM EDT BioVaxys Engages Life Sciences Public Relations and Market Communications Firm PR Newswire

Sep 17, 2021

03:00AM EDT BioVaxys Cancer Vaccine Manufacturing Partner Bio Elpida Reaches Bioproduction PR Newswire

Sep 14, 2021

03:02AM EDT BioVaxys Partner WuXi Biologics Completes Synthesis Of Recombinant SARS-CoV-2 S-proteins For BVX-0320 &CoviDTH Programs RTTNews

03:01AM EDT BioVaxys Bioproduction Partner WuXi Biologics Completes Synthesis Of PR Newswire

Sep 7, 2021

08:09AM EDT BioVaxys:Study In Humans Shows DTH Response Highly Durable And Persists For At Least One Year After COVID-19 Exposure RTTNews

08:03AM EDT highly durable and persists for at least one year after COVID-19 exposure or vaccine administration PR Newswire

Aug 3, 2021

08:02AM EDT cell-mediated immune response to SARS-CoV-2 is safe and effective in humans PR Newswire

Jul 28, 2021

11:01PM EDT BioVaxys Closes Final Tranche Of Non-Brokered Private Placement PR Newswire

Jul 22, 2021

09:18AM EDT FDA Provides Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Trials Of CoviDTH RTTNews

09:16AM EDT FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For PR Newswire

Jun 28, 2021

10:06PM EDT BioVaxys Announces Non-Brokered Private Placement PR Newswire

Jun 14, 2021

08:01AM EDT BioVaxys Receives Positive FDA Response For Pre-IND Review For CoviDTH Clinical PR Newswire

Jun 1, 2021

08:02AM EDT Facility To Produce Clinical Supply For Planned Ovarian Cancer Vaccine Study PR Newswire

May 24, 2021

08:01AM EDT Biovaxys Strengthens Internal Expertise With Appointment Of Scientific Advisor PR Newswire

May 20, 2021

08:02AM EDT BioVaxys Announces Appointment of Policy Advisor PR Newswire

May 19, 2021

08:01AM EDT BioVaxys Announces Uplisting To The OCTQB Venture Market PR Newswire

May 3, 2021

08:01AM EDT BioVaxys And BioElpida Sign Definitive Exclusive Agreement To Begin Ovarian PR Newswire

Apr 29, 2021

08:24AM EDT BioVaxys Broadens Intellectual Property Portfolio Commercial Trademark PR Newswire

Share